MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Bristol Myers Squibb Canada (BMS) and Acceleron Pharma Inc. (NASDAQ:XLRN) announced today that Health Canada has approved REBLOZYL® (luspatercept) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback